# BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q1 Results, Advances CNM-Au8 Toward Potential Accelerated Approval for ALS

Clene (NASDAQ: CLNN) announced first quarter 2025 financial results and progress on its CNM-Au8 program for ALS and MS. The company is preparing for a potential NDA submission under the FDA’s Accelerated Approval pathway for ALS in Q4 2025, supported by survival data and upcoming biomarker analysis. New data also showed CNM-Au8 significantly improved survival in patients with more severe ALS. In MS, Clene presented Phase 2 extension results demonstrating remyelination and neuronal repair. The company reported a Q1 net loss of $0.8 million on reduced expenses and $9.8 million in cash, funding operations into Q3 2025.

 To view the full press release, visit https://ibn.fm/ysWOi

 About Clene Inc.

 Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

 NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-clene-inc-nasdaq-clnn-reports-q1-results-advances-cnm-au8-toward-potential-accelerated-approval-for-als/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/clene-announces-promising-results-for-cnm-au8-program-in-als-and-ms/04ca5d7165f92e60bdfc4a26e29c01e8) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1khsjcq/clene_announces_promising_results_for_cnmau8/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/8/jolto6I2.webp)